• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Public Health

New obesity framework may reclassify over half of overweight individuals as people with obesity

byAdrian WongandThomas Su
July 14, 2025
in Public Health
Reading Time: 3 mins read
Colonic byproduct may decrease long-term weight gain
Share on FacebookShare on Twitter

1. In this cross-sectional study, a new obesity framework from the European Association for the Study of Obesity reclassified an additional nearly one-fifth of the United States population as obese.

2. The newly classified people with obesity had a higher mortality risk compared with adults with normal weight and no comorbidities, although they had similar risk to adults with normal weight and comorbidities.

Evidence Rating Level: 3 (Average)

Study Rundown: The European Association for the Study of Obesity (EASO) recently released a new framework defining obesity either as body mass index (BMI) ≥30 kg/m2 or as BMI between 25 and 30 kg/m2 with an elevated waist-to-height ratio (WtHR) and the presence of any medical, functional, or psychological complications. This study aimed to compare the population of individuals with obesity according to the existing definition and the EASO definition, and examine the complications prevalent within the newly defined subset. Among a sample of American adults, over one-third of the population was considered PWO per BMI alone; the new definition led to almost an additional twenty percent of the population being reclassified as PWO. Of the one-third of individuals who were considered overweight by BMI alone, over half were PWO; these individuals were generally older compared to those who were considered overweight or PWO per BMI alone. The newly classified PWO were more likely to have comorbidities, with the most common being hypertension and arthritis. Among patients considered overweight who were not reclassified as PWO, the majority met the WtHR ratio but did not meet the morbidity requirement. The newly reclassified PWO had a higher mortality compared with individuals with normal weight and no comorbidities, but similar mortality to that of individuals with normal weight who had comorbidities. The generalizability of this study was limited by potential confounding, the cross-sectional design, and missing data. Overall, this study clarified how the new EASO framework affected the apparent population makeup of PWO.

Click to read the study in AIM

Relevant Reading: A new framework for the diagnosis, staging and management of obesity in adults

RELATED REPORTS

A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality

Borderline-low hemoglobin levels linked to increased mortality

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

In-Depth [cross-sectional study]: This study aimed to determine how the new EASO framework affected the population distribution of individuals with overweight and obesity. The patient population was sampled from the National Health and Nutrition Examination Survey (NHANES), made up of individuals aged between 18 and 79 years.  The EASO framework defined normal as BMI between 18.5 and 25 kg/m2, overweight as BMI between 25 and 30 kg/m2 with WtHR <0.5 or without comorbidities, and obesity as BMI ≥30 kg/m2 or between 25 and 30 kg/m2 with WtHR ≥0.5 and at least 1 comorbidity. After applying exclusion criteria, the final sample was 44,030 individuals. Based on BMI alone, 31.3% of the study population was considered normal weight, 33.3% overweight, and 35.4% PWO. Applying the EASO framework caused 18.8% of participants (56.4% of people with overweight) to be reclassified as PWO, meaning that 54.2% of participants were now considered PWO. More men (21.9%) than women (15.6%) were newly classified as PWO; the newly classified PWO were older (51.3 years; standard deviation [SD], 14.5) than persons defined as overweight (36.5 years; SD, 12.2) or PWO (45.4 years; SD, 15.0) based on BMI alone. Among the newly classified PWO, 57.5% had at least 1 comorbidity and 42.5% had more than 1, compared with 34.3% and 38.7%, respectively, among PWO based on BMI alone. Compared with individuals with normal weight and no comorbidities, both the newly classified PWO (adjusted HR, 1.50 [95% CI, 1.20 to 1.88]) and individuals with BMI ≥30 kg/m2 (adjusted HR, 1.82 [95% CI, 1.46 to 2.27]) had higher mortality risk, which was not significantly different from the mortality risk among individuals with normal weight and comorbidities (HR, 1.74 [95% CI, 1.34 to 2.22]). Both the newly classified PWO (adjusted HR, 1.77 [95% CI, 1.36 to 2.32]) and individuals with BMI ≥30 kg/m2 (adjusted HR, 1.76 [95% CI, 1.36 to 2.29]) had increased mortality risk compared with individuals who remained classified as overweight. These effects were consistent across subgroup analyses.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: body mass index (BMI)mortalityobesityoverweightwaist circumferencewaist-to-hip ratio
Previous Post

Digital health apps may have limited role in reduction of migraine symptoms

Next Post

2 Minute Medicine Rewind July 14, 2025

RelatedReports

Emergency

A lower threshold for referral to the emergency department for outpatient hyperkalemia may reduce mortality

September 16, 2026
Cardiology

Borderline-low hemoglobin levels linked to increased mortality

September 14, 2026
Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source
Cardiology

The mortality in-hospital for patients undergoing elective catheter ablation for atrial fibrillation is low

September 4, 2026
“Housing First” linked to housing stability for homeless youth with mental illness
Public Health

Mortality in the post-housing period is high among homeless people in Ottawa, Canada

August 31, 2026
Next Post
Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults

2 Minute Medicine Rewind July 14, 2025

#VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis

#VisualAbstract: Brain Activation Measured on Functional MRI Predicts Response to Certolizumab, a TNF Inhibitor, in Rheumatoid Arthritis

Type 2 diabetes and abnormal amyloid concentrations are associated with accelerated brain atrophy

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • An ultrasound-guided percutaneous method of vagal nerve stimulation may be effective for refractory chronic pain
  • Daraxonrasib extends survival in metastatic pancreatic cancer
  • Artificial intelligence (AI) scribes showed mixed effects on documentation time and improvements in physician well-being
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.